Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: PLoS one. 10, 2015., 7., S. 1-13
- Ereignis
-
Veröffentlichung
- (wo)
-
Reutlingen
- (wer)
-
Hochschule Reutlingen
- (wann)
-
2015
- Urheber
-
Bach, Jan-Philipp
Gold, Maike
Mengel, David
Hattesohl, Akira
Lubbe, Dirk
Schmid, Severin
Tackenberg, Björn
Rieke, Jürgen
Maddula, Sasidhar
Baumbach, Jörg Ingo
- DOI
-
10.1371/journal.pone.0132227
- URN
-
urn:nbn:de:bsz:rt2-opus4-4606
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bach, Jan-Philipp
- Gold, Maike
- Mengel, David
- Hattesohl, Akira
- Lubbe, Dirk
- Schmid, Severin
- Tackenberg, Björn
- Rieke, Jürgen
- Maddula, Sasidhar
- Baumbach, Jörg Ingo
- Hochschule Reutlingen
Entstanden
- 2015
Ähnliche Objekte (12)
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Towards enabling precision medicine in Alzheimer's disease and Parkinson's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Towards enabling precision medicine in Alzheimer's disease and Parkinson's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Towards enabling precision medicine in Alzheimer's disease and Parkinson's disease